Objective: To compare the efficacy and safety of silodosin against tamsulosin as medical expulsion therapeutic agent in stone lower 1/3rd ureter. Patients and Methods: One hundred fifty patients divided equally into 2 groups I and II received silodosin 8 mg and tamsulosin 0.4 mg respectively. Patients aged 18 years or older having single unilateral stone 10 mm or less were included in the study. Patients with bilateral or multiple stones, marked hydronephrosis, previous open or endoscopic surgery and having urinary infection were excluded. Patients were followed weekly for 4 weeks by ultrasonography, plain radiography of the urinary tract and CT of the urinary tract when indicated. Results: Silodosin showed better results against tamsulosin as stone expulsion rate in silodosin and tamsulosin groups was 82.4 and 61.5% respectively with significant difference (p = 0.007). Also, the stone expulsion time was significantly lower in silodosin against tamsulosin groups as it was 9.4 ± 3.8 vs. 12.7 ± 5.1 days in group I and II respectively (p = 0.001). The adverse effects were comparable with non-significant more retrograde ejaculation in the silodosin group. Conclusion: Silodosin showed better efficacy in the stone expulsion rate and time with comparable safety of both drugs, with nonsignificant more retrograde ejaculation in silodosin.

Keywords:
Medical expulsion therapy, Urolithiasis, Silodosin , Tamsulosin, Distal ureteral stones
1.
Menon M, Parulkar BG, Drach DW: Urinary Lithiasis: Etiology, Diagnosis and Medical Management. Campbell’s Urology, ed 7. Philadelphia, WB Saunders, 1998, Vol. 3, p 2702.
2.
Erturhan S, Erbagci A, Yagci F, Celik M, Solakhan M, Sarica K: Comparative evaluation of efficacy of use of tamsulosin and/or tolterodine for medical treatment of distal ureteral stones. Urology 2007; 69: 633–636.
3.
Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, et al: Ureteral stones clinical guidelines panel summary report on the management of ureteral calculi. The American Urological Association. J Urol 1997; 158: 1915–1921.
4.
Dellabella M, Milanese G, Muzzonigro G: Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol 2005; 174: 167–172.
5.
Itoh Y, Kojima Y, Yasui T, et al: Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol 2007; 14: 749–753.
6.
Yilmaz E, Batislam E, Basar MM, et al: The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol 2005; 173: 2010–2012.
7.
Sasaki S, Tomiyama Y, Kobayashi S, et al: Characterization of α1-adrenoceptor subtypes mediating contraction in human isolated ureters. Urology 2011; 77: 762.e13–e17.
8.
De Sio M, Autorino R, Di Lorenzo G, et al: Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience. J Endourol 2006; 20: 12–16.
9.
Tsuzaka Y, Matsushima H, Kaneko T, et al: Naftopidil vs silodosin in medical expulsive therapy for ureteral stones: a randomized controlled study in Japanese male patients. Int J Urol 2011; 18: 792–795.
10.
Hollingswarth JM, Rogers MA, Kaufman SR, et al: Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006; 268: 1171–1179.
11.
Trinchieri A, Ostini F, Nespoli R, Montanari E, Zanetti G: A prospective study of recurrence rate of risk factors for recurrence after a first renal stone. J Urol 1999; 162: 27–30.
12.
Dell’Atti L: Silodosin versus tansulosin as medical expulsive therapy for distal ureteral stones: a prospective randomized study. Urologia 2015; 82: 54–57.
13.
Tzortzis V, Mamoulakis C, Rioja J, et al: Medical expulsive therapy for distal ureteral stones. Drugs 2009; 69: 677–692.
14.
Hubner WA, Irby P, Stoller ML: Natural history and current concepts for the treatment of small ureteral calculi. Eur Urol 1993; 24: 172–176.
15.
Seitz C, Liatsikos E, Propiglia F, et al: Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol 2009; 56: 455–471.
16.
Bensalah K, Pearle M, Lotan Y: Cost effectiveness of medical expulsive therapy using alpha blockers for the treatment distal ureteral stones. Eur Urol 2008; 53: 411–418.
17.
Wolf JS Jr: Treatment selection and outcomes: ureteral calculi. Urol Clin N Am 2007; 34: 421–430.
18.
Griewan MS, Singh SK, Paul H, Pawar DS, Verman M: The efficacy of tamsulosin in lower ureteral calculi. Urol Ann 2010; 2: 63–66.
19.
Gupta S, Lodh B, Singh AK, Somarendra K, Meitei SK, Singh SR: Comparing the efficacy of tamsulosin and silodosin in the medical expulsive therapy for ureteral calculi. J Clin Diagn Res 2013; 7: 1672–1674.
20.
Kumar S, Jayant K, Agrawal MM, Singh SK, Agrawal S, Parmar KM: Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stones: a randomized trial (a pilot study). Urology 2015; 85: 59–63.
21.
Imperatore V, Fusco F, Creta M, Di Meo S, Bounopane R, Longo N, et al: Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin. Arch Ital Urol Androl 2014; 86: 103–107.
22.
Sur RL, Shore N, L’Esperance J, Knudsen B, Gupta M, Olsen S, et al: Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial. Eur Urol 2015; 67: 959–964.
23.
Elgalaly H, Saki A, Fawzi A, Salem EA, Desoky E, Shahin A, Kamel M: Silodosin vs tamsulosin in the management of distal ureteric stones: a prospective randomised study. Arab J Urol 2016; 14: 12–17.
24.
Huang W, Xue P, Zong H, Zhang Y: Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis. Br J Clin Pharmacol 2016; 81: 13–22.
25.
Chapple CR, Montorsi F, Tammela TL, et al: Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo and active-controlled clinical trial performed in Europe. Eur Urol 2011; 59: 342–352.
26.
Yoshida M, Kudoh J, Homma Y, et al: Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin Interv Aging 2011; 6: 161–72.
27.
Rossi M, Roumeguere T: Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther 2010; 4: 291–297.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.